WuXi XDC Cayman stock
Price history
−13.60% over the period1 year: from $69.10 (November 20, 2025) to $59.70 (November 20, 2026), −13.60%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $59.70 |
| October 30, 2026 | $66.65 |
| September 30, 2026 | $82.00 |
| August 31, 2026 | $69.95 |
| July 31, 2026 | $51.80 |
| June 30, 2026 | $57.05 |
| May 29, 2026 | $54.90 |
| April 30, 2026 | $58.90 |
| March 31, 2026 | $58.20 |
| February 27, 2026 | $63.15 |
| January 30, 2026 | $62.80 |
| December 31, 2025 | $60.70 |
| November 28, 2025 | $65.45 |
| November 20, 2025 | $69.10 |
At a glance
The company
Contract research, development and manufacturing organization specializing in antibody drug conjugates and related bioconjugate therapies
Latest results
Quarter to June 30, 2025 · EPS ¥0.57 (estimate ¥0.54)
TickerLandia's take on WuXi XDC Cayman
- Pricier than similar companies: trailing 12-month P/E 47 vs 32 (+47%) in a group of 10.
- Strong point: Financial strength (91/100 in its group). Weak point: Earnings stability (48/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−30.26% from the 52-week high
Analysts · 21 analysts
Average target$92.94+55.68% vs. price
Buy 21 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: WuXi XDC Cayman
Compared with similar companies: very high financial strength.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh77
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 34.9 98 Forward P/E 23.5 54 Price/book 5.67 67 Price/sales 10.9 83 P/E (trailing 12 months) 46.6 81 Profitabilityhigh73
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 36.5% 35 Operating margin 28.1% 91 Net margin 22.4% 91 ROE 16.3% 67 ROA 9.3% 80 Earnings stabilityaverage48
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.5% 35 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthhigh69
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +81.73% 98 Earnings growth (year over year) +5.30% 18 Revenue growth (year over year) +37.00% 91 Financial strengthvery high91
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 95.5 98 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.83 94 Current ratio 2.46 76 Debt/equitycounts in reverse: lower means more financial strength 0.05 94 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumaverage51
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −2.48% 42 Relative strength (6 months) +18.43% 79 Distance from 200-day average −5.16% 55 1-year return −13.60% 28 Riskhigh67
How much the price swings.
Metric Value Position in group Volatility (60 days) 50.5% 72 Beta (1 year) 1.17 72 Maximum drawdown (12 months) 39.5% 58
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
WuXi XDC Cayman is pricier than similar companies
WuXi XDC Cayman's P/E (trailing 12 months): 46.6, +47% against the median of a group of 10 similar companies (31.8).
Compared with 10 similar companies
| Metric | WuXi XDC Cayman | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 46.6 | Middle | |
| Forward P/E | 23.5 | Middle | |
| Operating margin | 28.1% | High | |
| ROE | 16.3% | Middle | |
| Debt/equity | 0.05 | Low |
Grey band: the middle half of the group; tick: the median; dot: WuXi XDC Cayman. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥3.7B
Latest quarter · Q2 2026
Net income
¥819.28M
Latest quarter · Q2 2026
Quarterly net margin
22.1%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $75.6B
- P/E
- 46.6
- EPS
- $1.28
- Volume
- 6.32M
- Daily trading
- €39.77M
- Dividend yield
- 0.00%
How WuXi XDC Cayman is changing
All resultsRevenue grew 128.1% a year on average over the last 5 years
Operating margin rose from 12.7% to 27.3%
Less cash than profit: free cash flow equal to -16% of net income
Returns
WuXi XDC Cayman returns
$1,000 invested in WuXi XDC Cayman 3 years ago, on November 20, 2023, would be worth $2,132 today: +113.21% in total, +28.70% per year. This is the price return only: dividends are excluded.
| Period | WuXi XDC Cayman | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −21.29% | −6.10% | $787 |
| 6 months | +3.47% | −12.63% | $1,035 |
| Year to date | −1.65% | −12.56% | $984 |
| 1 year | −13.60% | −13.26% | $864 |
| 3 years | +113.21% | +26.06% | $2,132 |
Over the last 6 months it has done better than 83% of the stocks in the Industrials sector.
Price only, without dividends. Calculate your investment
The chart in detail
WuXi XDC Cayman: technical analysis
WuXi XDC Cayman shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 29.8% below its all-time closing high ($85.10, October 3, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 29
- Below 30: a strong fall in a short time
- vs 200-session average
- −5.16%
Active signals
Close below the low of the previous 55 sessions.
RSI below 30: the stock has fallen a lot in a short time.
Support and resistance
Price areas where WuXi XDC Cayman has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$69.00+15.58%3 touches, last on September 11, 2026
- Resistance$65.84+10.28%4 touches, last on August 10, 2026
- Resistance$61.58+3.15%5 touches, last on November 3, 2026
- Last price$59.70
- Support$58.35−2.26%2 touches, last on May 20, 2026
- Support$55.53−6.99%2 touches, last on April 24, 2026
- Support$52.00−12.90%2 touches, last on July 17, 2026
Volatility and risk
Over the last year it has moved roughly in line with the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.17
- Volatility (60 sessions, annualised)
- 50.5%
- Largest fall in the last year
- −39.49%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
WuXi XDC Cayman and its competitors
Operating in China, North America, Europe and other international markets, WuXi XDC Cayman Inc. provides contract research, development and manufacturing services. Its work covers the discovery, development and production of drug substances and drug products built on antibody-drug conjugates, bioconjugates and monoclonal antibody intermediates, along with payload-linker components. The company also develops and markets anti-tumor drugs and offers international sales contracting services. It has a strategic collaboration with Earendil Labs and with Akari Therapeutics.
- Headquarters
- Wuxi, China
- Employees
- 3,628
- Founded
- 2013
- Chief executive
- Jincai Li
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| WuXi XDC Cayman2268 | $9.64B | 28.1% | 46.6 | +3.47% |
| Sonic HealthcareSHL | $7.13B | 9.3% | 17.6 | +17.41% |
| WuXi AppTec603259 | $63.99B | 44.8% | 15.7 | +36.57% |
| QiagenQIA | $10.23B | 26.7% | 28.5 | +50.69% |
| bioMérieuxBIM | $11.82B | 16.0% | 23.4 | +25.67% |
| ICON PublicICLR | $13.99B | 2.7% | 74.7 | +62.23% |
Same industry or related industries, similar size. Compare WuXi XDC Cayman with its competitors · Full profile
